araag2/HINT huggingface dataset:
Clinical trial NCT00498407 (phase 2, status: completed)
Conditions: advanced colorectal cancer, colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cp-4055
SMILES: [H]\C(CCCCCCCC)=C(\[H])CCCCCCCC(=O)OC[C@@]1([H])O[C@@]([H])(N2C=CC(=N)N=C2O)[C@@]([H])(O)[C@]1([H])O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed metastatic CRC who have failed
             a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU)
             with or without bevacizumab, with or without other Investigational Medicinal Products
             (IMPs)

          2. Measurable disease according to Response Criteria In Solid Tumours (RECIST)

          3. Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group)
             Performance Status

          4. Age 18 years or more

          5. Life expectancy > 3 months

          6. Signed informed consent (IC)

          7. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to
             CP-4055 treatment. Nursing patients are excluded.

          8. Male and female patients must use acceptable contraceptive methods for the duration of
             time on study, and males also for 3 months after the last CP-4055 dose

          9. Adequate haematological and biological functions

        Exclusion Criteria:

          1. Known brain metastases

          2. Radiotherapy to more than 30 % of bone marrow

          3. Participation in another therapeutic clinical study within 30 days of enrolment or
             during this clinical study

          4. Concomitant treatment with a non-permitted medication:

               -  Alternative drugs

               -  High doses of vitamins

          5. History of allergic reactions to ara-C or egg

          6. Any serious concomitant systemic disorders incompatible with the clinical study (e.g.
             uncontrolled inter-current illness including ongoing or active infection)

          7. Any significant central nervous system or psychiatric disorder(s) that would hamper
             the patient's compliance

          8. Pregnancy, breastfeeding or absence of adequate contraception for both male and female
             fertile patients

          9. Known positive status for HIV and/or hepatitis B or C

         10. Drug and/or alcohol abuse

         11. Any reason why, in the investigator's opinion, the patient should not participate
Clinical trial NCT00088582 (phase 2, status: completed)
Conditions: acromegaly
ICD codes: E22.0
Drugs: pasireotide (som230), octreotide (sandostatin)
SMILES: NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with active acromegaly due to a pituitary adenoma

          -  Patients who have been previously treated for acromegaly with certain medications may
             be required to be without certain medications prior to entering the study

        Exclusion Criteria:

          -  Patients with compression of the optic chiasm causing any visual field defect

          -  Patients who require a surgical intervention for relief of any sign or symptom
             associated with tumor compression

          -  Patients who have received radiotherapy in the 2 years prior to the start of the trial

          -  Patients who have congestive heart failure, unstable angina, cardia arrhythmia, or a
             history of acute myocardial infarction within the three months preceding enrollment

          -  Patients with gallstone disease

          -  Patients with chronic liver disease

          -  Known hypersensitivity to Sandostatin or Sandostatin LAR

          -  Female patients who are pregnant or lactating, or are of childbearing potential and
             not practicing a medically acceptable method of birth control and highly effective
             method for birth control

          -  History of immunocompromise, including a positive HIV test result

          -  Patients who have a history of alcohol or drug abuse in the six-month period prior to
             the enrollment visit

          -  Patients who have participated in any clinical investigation with an investigational
             drug within 4 weeks prior to dosing
Clinical trial NCT01104675 (phase 2, status: completed)
Conditions: ovarian cancer, fallopian cancer, peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: enmd-2076
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC(=CC=C12)[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer
             that is platinum resistant.

          -  Have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual
             left ventricular ejection fraction of greater than or equal to the institution lower
             limit of normal

          -  Greater than or equal to 18 years of age

          -  Have clinically acceptable laboratory screening results

          -  Have an ECOG performance status of 0 or 1

          -  Able to tolerate oral medications

        Exclusion Criteria:

          -  Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or
             diastolic blood pressure greater than 100mmHg); require two or more antihypertensive
             medications to control hypertension (including ACE inhibitors, beta blockers, calcium
             channel blockers, or diuretics)

          -  Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater
             than 470 msec

          -  Have active, acute, or chronic clinically significant infections or bleeding

          -  Have persistent 2+ protein by urinalysis or a history of nephrotic syndrome
Clinical trial NCT01046136 (phase 2, status: completed)
Conditions: common cold
ICD codes: J00, T48.5X6S, T48.5X3S, T48.5X4S, T48.5X5S, T48.5X6A, T48.5X6D
Drugs: guaifenesin (mucinex), placebo
SMILES: COC1=CC=CC=C1OCC(O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  common cold symptoms

          -  meet symptom severity

          -  females of child-bearing potential must have negative pregnancy test and use effective
             birth control

        Exclusion Criteria:

          -  chronic respiratory conditions

          -  significant heart, kidney, liver, or lung disease, uncontrolled hypertension or
             diabetes, cystic fibrosis, thyroid disorder

          -  pregnant or lactating

          -  known malignancy

          -  participation in any other clinical trial within 30 days of baseline

          -  related to another enrolled patient or persons involved directly or indirectly with
             the conduct of this study
Clinical trial NCT00123630 (phase 2, status: completed)
Conditions: esophagitis
ICD codes: B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: omalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects aged 12-60 years of age with EE as defined above

          -  Serum IgE level 30-700 IU/mL

          -  Subjects with acceptable medical history, physical exam and laboratory test results

          -  No history of bleeding diathesis, significant cardiopulmonary disease, or other
             contraindication to upper endoscopy

        Exclusion Criteria:

          -  Need for esophageal dilation at enrollment due to food impaction or inability to pass
             endoscope

          -  Inability of subject to provide informed consent (if ages 18-60), or inability of
             children (ages 12-17) to provide assent

          -  History of esophagogastric surgery

          -  Presence of other esophageal pathology that could account for patients' symptoms
             including eosinophil infiltration due to gastroesophageal reflux disease (GERD)

          -  Incarceration

          -  Pregnancy

          -  Women of childbearing potential not using the contraception method(s)

          -  Patients with elevated serum IgE levels for reasons other than atopy

          -  Patients taking cromolyn sodium or nedocromil sodium within 1 month of visit 1

          -  Patients taking oral or topical corticosteroids within one month of visit 1

          -  Patients taking leukotriene receptor inhibitors within one month of visit 1

          -  Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study

          -  Patients with a history of noncompliance to medical regimens or who were considered
             potentially unreliable

          -  Use of any other investigational agent in the last 30 days

          -  Patients with a known hypersensitivity to any ingredient of rhuMAb-E25, study rescue
             medication

          -  Patients with Barrett's esophagus will be excluded if found endoscopically or
             pathologically at biopsy

          -  Currently treated with omalizumab or treated with omalizumab within the past 6 months.
Clinical trial NCT00345748 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients with active Rheumatoid Arthritis while on methotrexate having 12 tender and
             10 swollen joints at randomization

        Exclusion Criteria:

          -  no current infection or other evolutive or uncontrolled disease
Clinical trial NCT01999894 (phase 2, status: completed)
Conditions: autism, pediatric autism
ICD codes: Z13.41
Drugs: memantine hcl
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Completed lead-in study MEM-MD-57A (NCT00872898)

          -  A knowledgeable caregiver capable of providing reliable information about the
             patient's condition, able to attend all clinic visits with the patient

        Exclusion Criteria:

          -  Patients with a concurrent medical condition that might interfere with the conduct of
             the study
Clinical trial NCT00228423 (phase 2, status: completed)
Conditions: atherosclerosis
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: clopidogrel 75 mg daily, water pill daily
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts,
             with or without the use of cardiopulmonary bypass.

        Exclusion Criteria:

          -  Emergency surgery

          -  Valve surgery

          -  Redo CABG

          -  Left ventricle ejection fraction < 25%

          -  Serum creatinine > 130 µmol/L

          -  Preoperative use of clopidogrel (with the exception of the current admission)

          -  Preoperative use of warfarin; allergy to aspirin or clopidogrel.

          -  History of cerebrovascular accident

          -  History of severe liver disease

          -  Morbid obesity

          -  Current malignancy
Clinical trial NCT00430495 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: atacicept, atacicept, atacicept, placebo matched to atacicept
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Rheumatoid arthritis (RA) satisfying American College of Rheumatology (ACR) diagnostic
             criteria with a disease history of at least one year

          2. Male or female greater than or equal to (>=)18-years of age at time of informed
             consent

          3. Active RA as defined by:

               -  >=8 swollen joints (66-joint count),

               -  >=8 tender joints (68-joint count), and

               -  C-reactive protein (CRP) >=10 milligram per liter (mg/L) (central laboratory)
                  and/or erythrocyte sedimentation rate (ESR) >= to 28 millimeter per hour (mm/h)

          4. Failure of at least one TNFa antagonist therapy (previously or at the time of
             screening) as specified in the protocol

          5. Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          1. Any condition, including laboratory findings or findings in the medical history or
             pre-trial assessments, that in the opinion of the Investigator constitutes a risk or a
             contraindication for the subject's participation in the trial or that could interfere
             with the trial objectives, conduct or evaluation

          2. Treatment with biologics aiming at B cell modulation such as rituximab or belimumab
             within 2 years before study Day 1

          3. Any previous treatment with anakinra (Kineret), abatacept (Orencia) or tocilizumab
             within 3 months before study Day 1

          4. Use of etanercept (Enbrel) within 28 days before study Day 1, or of infliximab
             (Remicade) or adalimumab (Humira) within 60 days before study Day 1

          5. Participation in any interventional clinical trial with an unapproved investigational
             therapy within the 3 months before the start of this study (or within 5 half-lives of
             the investigated compound before study Day 1, whichever is longer)

          6. Other protocol defined exclusion criteria could apply
Clinical trial NCT00454324 (phase 2, status: terminated)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, abraxane
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Histological or cytological diagnosis of extensive stage small-cell lung cancer
             (ES-SCLC),* including malignant pleural effusion

          2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          3. No prior systemic chemotherapy, immunotherapy, or biological therapy for SCLC

          4. Measurable disease as defined by the RECIST criteria

          5. Adequate organ function as defined by the protocol

          6. Female patients of child bearing potential (CBP) must agree to use of reliable method
             of birth control during and for 3 months following treatment

          7. Patients must sign informed consent document

          8. Patients must be ≥ 18 years of age

          9. Patients with brain metastases that have been adequately treated and are determined to
             be controlled by the attending physician are eligible

         10. Patients who have had prior malignancies are eligible if they are ≥ 5 years from
             diagnosis free of disease or the attending physician believes the patient's prognosis
             is best defined by the ES-SCLC (if questions concerning this eligibility criteria
             arise, please contact the principal investigator)

        (*)ES-SCLC defined as metastases outside the chest, pulmonary metastases, or contralateral
        metastases (supraclavicular or hilar) nodes that could not be included with a reasonable
        single radiation port. Patients with malignant pleural effusions are considered extensive
        stage.

        Exclusion Criteria:

          1. Received treatment within the last 30 days with a drug that has not received Food and
             Drug Administration (FDA) approval for any indication at the time of study entry

          2. Pregnancy or breast feeding

          3. Serious active infection that would require a prolonged course (4-6 weeks) of
             antibiotics or would compromise the safety of the patient or compromise the patient's
             ability to complete the study

          4. Symptomatic brain metastases

          5. Grade ≥ 2 neuropathy using NCI CTCAE version 3.0 criteria

          6. Previous anaphylactic reaction to carboplatin, paclitaxel, and docetaxel

          7. Severe or uncontrolled cardiac disease, defined as uncontrolled or unstable angina,
             myocardial infarction in the last month, uncontrolled congestive heart failure (≥ 3
             admissions for congestive heart failure in the 3 months prior to diagnosis)
Clinical trial NCT01609140 (phase 2, status: completed)
Conditions: coronary heart disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: mpsk3169a, mpsk3169a, mpsk3169a, mpsk3169a, mpsk3169a, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Use of a standard-of-care statin at a stable dose, or intolerance of statins, without
             use of other lipid modifying therapies

          -  Fasting LDL cholesterol 90-250 mg/dL on the statin regimen above

        And at least one of the following:

          -  Coronary heart disease (CHD) with a history of myocardial infarction (MI),
             percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG),
             or prior coronary angiography demonstrating coronary atherosclerosis

          -  A CHD risk equivalent condition, including diabetes mellitus (type 1 or 2), chronic
             kidney disease, prior stroke, carotid disease, peripheral arterial disease, or
             abdominal aortic aneurism

          -  >/=2 CHD risk factors (age >/= 45 years for men or >/= 55 years for women; smoking;
             hypertension; low HDL cholesterol; family history of premature CHD) and a high risk of
             a CV event based on risk estimation systems

        Exclusion Criteria:

          -  Severe congestive heart failure (NYHA Class III-IV) or left ventricular ejection
             fraction </= 35%

          -  Recent (within 3 months) MI, unstable angina, stroke, transient ischemic attack, CABG,
             PCI, hospital admission for heart failure, major surgery, uncontrolled cardiac
             arrhythmia (other than atrial fibrillation or flutter), or initiation of renal
             replacement therapy (dialysis)

          -  Fasting serum triglyceride level >/= 400 mg/dL

          -  Homozygous familial hypercholesterolemia

          -  Poorly controlled diabetes mellitus, hypertension or thyroid disease

          -  Liver or muscle disease, including abnormal test results at screening

          -  Pregnant or lactating

        The above list is not intended to contain all factors relevant to a patient's eligibility
        for the study.
Clinical trial NCT00403104 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis (als)
ICD codes: G12.21
Drugs: ono-2506po, ono-2506po
SMILES: CCCCCC[C@@H](CCC)C(O)=O, CCCCCC[C@@H](CCC)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of clinically possible, clinically probable laboratory-supported, clinically
             probable or clinically definite ALS (according to WNF EL Escorial diagnostic criteria,
             revised according to the Airlie House Conference 1998)

          2. Onset of muscle weakness within 14 months randomization

          3. Concomitant standard Riluzole therapy (50mg twice daily)

        Exclusion Criteria:

          1. Presence of a tracheotomy, mechanical ventilation or non-invasive ventilation

          2. Requirement for prescription drugs used for potential neuroprotective benefit -
Clinical trial NCT00139711 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: irinotecan, docetaxel
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven NSCLC

          -  Recurrent or metastatic NCSLC

        Exclusion Criteria:

          -  Prior malignancies; except for cured non melanoma skin cancer, curatively treated in
             situ carcinoma of the cervix or other cancer adequately treated an with non evidence
             of disease for at least 5 years

          -  History or presence of brain or meningeal metastases
Clinical trial NCT00436293 (phase 2, status: completed)
Conditions: nasopharyngeal neoplasms
ICD codes: A36.1, B87.3
Drugs: docetaxel, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  International Union against Cancer stages III and IV newly diagnosed NPC

        Exclusion Criteria:

          -  Inadequate bone marrow reserve

          -  Inadequate renal function

          -  Other primary malignancy

          -  Evidence of distant metastases

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01003899 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: afatinib (bibw 2992)
SMILES: CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1
Eligibility criteria:

        Inclusion criteria:

          1. Pathologically confirmed stage IIIB/IV adenocarcinoma in non-small cell lung
             cancer[NSCLC]

          2. Progressive disease following a second-line cytotoxic chemotherapy including at least
             one platinum-containing regimen

          3. A known wild-type EGFR status

          4. Patients 18 years of age or older

        Exclusion criteria:

          1. More than two prior cytotoxic chemotherapy treatment regimens for relapsed or
             metastatic disease

          2. Prior treatment with EGFR targeting small molecules or antibodies

          3. Radiotherapy or surgery within 4 weeks prior to study entry

          4. Active brain metastasis

          5. Known pre-existing interstitial lung disease

          6. History or presence of clinically relevant cardiovascular abnormalities

          7. Cardiac left ventricular function with resting ejection fraction of less than 50%

          8. Absolute neutrophil count[ANC] < 1,500/mm3

          9. Platelet count <100,000/mm3

         10. Creatinine clearance<60ml/min or serum creatinine >1.5 times upper limit of normal

         11. Women of childbearing potential, or men who are able to father a child, unwilling to
             use a medically acceptable method of contraception during the trial

         12. Pregnancy or breast-feeding